Touchlight

This application note shows how to achieve comparable RNA yields using approximately half the template mass of plasmid DNA, while maintaining key RNA quality attributes. Same #RNA yield, half the template input. Explore the data: eu1.hubs.ly/H0zL5Xt0

Plasmid DNA has long been central to cell and gene therapy development. As manufacturing demands scale, many developers are re‑evaluating whether pDNA is still the best fit for speed, consistency, and long‑term resilience. Get insights in this Q&A article eu1.hubs.ly/H0zH5dT0

Whether you're producing mRNA templates, viral vectors, non-viral gene therapies, or DNA vaccines, the architecture of your starting material shapes everything downstream, from purity to GMP. Doggybone (dbDNA) is rewriting the rules of DNA manufacturing. eu1.hubs.ly/H0zH69k0

dbDNA™ technology eliminates biological limitations, ensuring high-purity, scalable DNA synthesis. Using enzymatic processes, Touchlight can deliver optimised DNA vectors to help bring cutting-edge genetic applications to fruition quickly. Explore here: eu1.hubs.ly/H0zzVb-0

Having issues with editing efficiency, long-term reconstitution & stem cell integrity in your HSC workflows? The choice of payload matters, with mbDNA achieving better engraftment in vivo following transplant. See the data in this on-demand webinar. eu1.hubs.ly/H0zxN640

As AAV therapies move toward commercial scale, DNA choice is becoming a manufacturing decision—not just a technical one. Discover why developers are rethinking DNA inputs to reduce process burden and improve scalability. eu1.hubs.ly/H0zs54k0

Meet the Touchlight team at booth #11 at #ESGCT2026. Learn more about our cell-free DNA technology and how we’re advancing DNA manufacturing for next-generation therapies. Showcasing three scientific posters. Schedule a meeting today. 🔗 eu1.hubs.ly/H0zqNmn0 #ESGCTHamburg2026

Plasmid DNA has long been central to cell and gene therapy development. As manufacturing demands scale, many developers are re‑evaluating whether pDNA is still the best fit for speed, consistency, and long‑term resilience. Get insights in this Q&A article eu1.hubs.ly/H0zpLVr0

Visit us at booth #11 at #ESGCT2026 & meet our team. Learn more about our cell-free DNA technology and how we’re advancing DNA manufacturing for next-generation therapies. Showcasing three scientific posters. Schedule a meeting today. 🔗 eu1.hubs.ly/H0zm4yZ0 #ESGCTHamburg2026

This On-Demand Webinar presents how Touchlight & ElevateBio are enabling safer & more effective Cell and Gene Therapies. Empower efficient, targeted genome editing for your gene therapies. Watch it now: eu1.hubs.ly/H0zm7VT0 #plasmiddna #syntheticdna #cellfreedna

Having issues with editing efficiency, long-term reconstitution & stem cell integrity in your HSC workflows? The choice of payload matters, with mbDNA achieving better engraftment in vivo following transplant. See the data in this on-demand webinar. eu1.hubs.ly/H0zkzd30

Touchlight announces today that Karen Fallen is stepping down as CEO & that Will Downie has been appointed Interim Chief Executive Officer. We thank Karen for her leadership, guidance and contributions to the building of Touchlight's CDMO business. eu1.hubs.ly/H0zfS_20

In a client study, Touchlight’s z- dbDNA™ generated 2× the mRNA yield of pDNA using copy-matched template amounts, delivering reduced dsRNA & comparable potency. Read the blog to learn how enzymatically produced cell-free DNA can help increase efficiency: eu1.hubs.ly/H0zf7WV0

Don't miss @PharmaronBio BioInnovate webinar on scaling AAV processes for advanced gene therapies. Peter Archibald, will share how dbDNA™ can increase AAV genome titres, improve full capsid percentages and reduce impurity packaging. Register here: eu1.hubs.ly/H0zb-bB0

Visit us at booth #11 at #ESGCT2026 & meet our team. Learn more about our cell-free DNA technology and how we’re advancing DNA manufacturing for next-generation therapies. Showcasing three scientific posters. Schedule a meeting today. 🔗 eu1.hubs.ly/H0z690n0 #ESGCTHamburg2026

Touchlight has won the Innovation Catalyst Award at #CPHIMilan! This recognition celebrates the innovation at the heart of what we do and the continued work of our team to advance DNA manufacturing and enable the next generation of genetic medicines. eu1.hubs.ly/H0yWGhX0

Heading to #BioJapan , find us at Booth# D-42. Our team will be on the ground, ready to talk cell-free DNA, from accelerating development timelines to scalable, high-purity DNA for next-gen gene therapies and vaccines. Schedule a meeting with our team: eu1.hubs.ly/H0yW6Nr0

Touchlight has won the CPHI Pharma Award for: Innovation Catalyst! Board member Will Downie accepted the award on our behalf. Congrats to all the award winners in 2026. eu1.hubs.ly/H0yVgn-0 #CPHIMilan #CPHIMilan2026 #PharmaAwards

As AAV therapies move toward commercial scale, DNA choice is becoming a manufacturing decision—not just a technical one. Discover why developers are rethinking DNA inputs to reduce process burden and improve scalability. eu1.hubs.ly/H0yV5CD0

Day 1 at Meeting on the Mesa is underway in Arizona🌵! We are all set up and ready to chat at Booth #M20. Stop by to learn how cell-free DNA technology is enabling faster, more flexible DNA supply for cell and gene therapy development. #MeetingOnTheMesa #CGMesa26